image: Incremental net monetary benefit of novel tuberculosis vaccines assessed from the societal perspective, for several willingness-to-pay thresholds. Note: Estimates include the iNMB from the countries that are cost-effective at the respective threshold. GDP per capita estimates from 2020. GDP, gross domestic product per capita; iNMB, incremental net monetary benefit. view more
Credit: Portnoy A, et al., 2023, PLOS Medicine, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)
In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004155
Article Title: The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study
Author Countries: United States, United Kingdom, Netherlands, Switzerland, China
Funding: see manuscript
Journal
PLOS Medicine
Method of Research
Computational simulation/modeling
Subject of Research
Not applicable
COI Statement
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Members of the funder (NG, MZ, SYS, RH, IGB, NN) participated as authors on the study and critically reviewed the analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted. All other authors have declared that no competing interests exist.